Skip to content

Piloting a Patient-Reported Outcome Measure for Opioid Use Disorder Recovery in a Clinical Setting

Piloting a Patient-Reported Outcome Measure for Opioid Use Disorder Recovery in a Clinical Setting

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05388045
Acronym
RecoveryPROM
Enrollment
100
Registered
2022-05-24
Start date
2022-04-14
Completion date
2023-11-01
Last updated
2023-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Use Disorder, Substance Use Disorders

Keywords

Patient reported outcome measure, Recovery, Measure development

Brief summary

Performance measure can improve quality of care at the patient, provider, and systems level of care, and patient-reported outcome measures bring a needed patient-centered focus. Recovery has been difficult to measure for people with substance use disorders, and is more challenging in the context of opioid use disorders (OUD) and treatment medications. This study will examine a recovery patient-reported outcome measure to determine if patients and clinicians find it useful and acceptable in the clinical context, and if it leads to improved outcomes.

Detailed description

The pilot clinical trial will test the newly developed Recovery Patient-Reported Outcome Measure (Recovery PROM) and approach with patients and clinicians in an office-based opioid medication treatment program (known as office-based opioid treatment (OBOT), medication-assisted treatment (MAT) or medications for OUD (MOUD)), in the specific context of buprenorphine treatment. Aims This is a pilot study to assess the feasibility of implementing the Recovery PROM into the workflow of a clinical setting, assess its initial effectiveness, and evaluate its value to patients and clinicians. The aims are as follows: 1. Work with a clinical partner to assess and refine the draft Recovery PROM, and examine feasibility and implementation (e.g., workflow, data transfer issues) related to its use in a clinical setting. 2. Determine initial effectiveness of the Recovery PROM for improving patient outcomes (self-efficacy, health-related quality of life, patient-provider relationship, social determinants of health, substance use) and facilitating self-directed care and patient-centered shared decision-making. 3. Evaluate and update (if needed) the Recovery PROM in terms of recovery while on OUD medication treatment, patient characteristics, and clinical workflow. Hypotheses Although this pilot study is primarily for information gathering, and ultimately refinement of the Recovery PROM and approach, the study has two broad hypotheses. H1. Patients and clinicians will find the Recovery PROM to be a useful tool for patient recovery. H2. Patient self-efficacy, shared decision-making, patient-provider relationship, and health-related quality of life will improve and substance use will decrease with the use of the Recovery PROM.

Interventions

A Recovery Patient-Reported Outcome Measure (PROM, 19 items and 2 questions for each item, collected via online survey) will be completed by eligible patients at baseline and again at months 3 and 6. The initial Recovery PROM will be shared with the clinician, at the visit most closely scheduled following the baseline visit, for review and discussion with the patient. At the 3- and 6-month visits, the clinician will be asked to re-review and compare the earlier Recovery PROM(s) as well as the current Recovery PROM. The clinician is encouraged to use the PROM results during interim clinical visits with the patient. Efforts will be made to contemporaneously track how often the PROM is discussed in clinical sessions conducted during the 6 months.

Sponsors

Stanley Street Treatment and Resources (SSTAR)
CollaboratorUNKNOWN
National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Brandeis University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Masking description

The intervention is not blinded to patients, clinicians, or investigators.

Intervention model description

No randomization is involved, with all eligible patients invited to participate.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients: * Taking buprenorphine for OUD treatment, in current episode of care at clinical partner site, for at least 6 weeks but less than 3 years. * Able and willing to provide informed consent. * Able to read English, to provide informed consent and complete study instruments. * Able to use a smart phone to complete study instruments \[phones with data plan will be provided for those without\].

Exclusion criteria

• Patients who do not meet inclusion criteria.

Design outcomes

Primary

MeasureTime frameDescription
Change in reported health related quality of life (4-point scale), assessed via CDC HRQOL questionnaire3 months after baseline, 6 months after baselineCenters for Disease Control & Prevention (CDC) Health Related Quality of Life (HRQOL) questionnaire, single item ranging from excellent (score=1) to poor (score=5).
Change in number of days mental/physical health were not good (in past 30 days), assessed via CDC HRQOL questionnaire.3 months after baseline, 6 months after baselineCDC Health Related Quality of Life (HRQOL) questionnaire, separate items for mental and physical health, single item measuring the number of days out of 30, where 0 is no days (better) and 30 is daily (worse).
Change in reported self-efficacy for managing chronic conditions, assessed via PROMIS Self-Efficacy measure3 months after baseline, 6 months after baselinePatient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy scale, a series of 10 questions each on a 5-point scale, ranging from not at all confident (score=1) to very confident (score=5).
Change in patient-clinician alliance, assessed via WAI-SR3 months after baseline, 6 months after baselineWorking Alliance Inventory-Short Revised (WAI-SR): Patient-clinician alliance for tasks and goals of treatment, and effective relationship. This scale is a series of 12 items, with responses ranging from seldom (score=1) to always (score=5).

Secondary

MeasureTime frameDescription
Social determinants of health, assessed via PRAPARE3 months after baseline, 6 months after baselineProtocol for Responding to and Assessing Patient Assets, Risks, and Experiences (PRAPARE). The prepare is a series of independent questions related to social determinants of health; it is not scored.
Substance use past 30 days, assessed via modified ASI Alcohol and Drug module3 months after baseline, 6 months after baselineModified Alcohol and Drug module of the Addiction Severity Index (ASI). The ASI asks how many days in the past 30 each substance was used, where 0 is no use (better) and 30 days is daily use (worse).

Other

MeasureTime frameDescription
Satisfaction with Recovery PROM6 months after baselineSelf-developed questions. These are independent questions. Each is scored on a scale of 1 to 5, where 1 is the best outcome (e.g., extremely satisfied) and 5 is the worst outcome (e.g., extremely unsatisfied).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026